Core Viewpoint - Haosen Pharmaceutical has been recognized as a national-level "specialized, refined, and innovative" small giant enterprise, which enhances its brand recognition and industry influence, positively impacting its overall development [1][2]. Group 1: Recognition and Impact - The company was previously recognized as a specialized and innovative small enterprise in Zhejiang Province in 2021 and has now achieved national-level recognition [1]. - This recognition by the Ministry of Industry and Information Technology acknowledges the company's technological level, innovation capability, manufacturing quality, and overall strength [1]. Group 2: Research and Development - In the first three quarters of 2025, the company invested a total of 28.1661 million yuan in research and development, representing a year-on-year increase of 57.96% [1]. - The company is pursuing a multi-channel and diversified approach to convert research outcomes into market value through collaborations with research enterprises and universities [1]. Group 3: Product Pipeline - As of June 30, 2025, the company has 17 products under research, including APIs, intermediates, and formulations, targeting various therapeutic areas such as antiviral, antidepressant, lipid-lowering, non-steroidal anti-inflammatory, anti-rheumatic, and anti-ulcer medications [1]. Group 4: Corporate Mission and Strategy - The company is committed to continuously researching, producing, and promoting excellent pharmaceutical products and services to enhance people's quality of life [2]. - It focuses on the research, production, and sales of chemical pharmaceutical raw materials, intermediates, and formulations, aiming for specialized development and increased R&D investment to strengthen its core competitiveness [2].

Core Viewpoint - Haisen Pharmaceutical (001367.SZ) has been recognized as a "Little Giant" enterprise in the seventh batch of specialized and innovative small and medium-sized enterprises by the Ministry of Industry and Information Technology of China [1] Group 1 - Haisen Pharmaceutical has successfully passed the certification for the seventh batch of specialized and innovative "Little Giant" enterprises [1] - The recognition is part of a broader initiative by the Ministry of Industry and Information Technology to identify and support innovative companies [1]

Group 1 - The core point of the article is that Haisen Pharmaceutical has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise by the Ministry of Industry and Information Technology, which enhances the company's brand recognition and industry influence [1] - Haisen Pharmaceutical was previously recognized as a specialized and innovative small enterprise in Zhejiang Province in 2021, indicating a consistent track record of innovation and capability [1] - The company's revenue composition for the first half of 2025 is entirely from the pharmaceutical manufacturing industry, indicating a focused business model [1] Group 2 - As of the report, Haisen Pharmaceutical has a market capitalization of 3.3 billion yuan [2]

证券代码：001367 证券简称：海森药业 公告编号：2025-062 浙江海森药业股份有限公司 关于公司被认定为国家级专精特新"小巨人"企业的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、基本情况 根据国家工业和信息化部发布的《工业和信息化部关于公布第七批专精 特新"小巨人"企业和2025年通过复核专精特新"小巨人"企业名单的通告》， 浙江海森药业股份有限公司（以下简称"公司"）通过第七批专精特新"小 巨人"企业认定。 二、对公司的影响 国家级专精特新"小巨人"企业是工业和信息化部为贯彻落实中共中央办公 厅、国务院办公厅《关于促进中小企业健康发展的指导意见》有关要求，经各省 级主管部门通过组织报送、专家评审及社会公示等流程而评选产生的专注于细分 市场、创新能力强、市场占有率高、掌握核心关键技术、质量效益优的排头兵企 业。 公司继被认定为 2021 年浙江省专精特新中小企业后，本次被认定为国家级 专精特新"小巨人"企业，是国家工业和信息化部对公司技术水平、创新能力、 生产制造水平及综合实力等多方面的认可，有利于提高公司的品牌知名度和在行 业内的影响 ...

Core Viewpoint - The company, Haisen Pharmaceutical (001367.SZ), has been recognized as a "Little Giant" enterprise through the seventh batch of specialized and innovative small and medium-sized enterprises certification [1] Group 1 - The recognition as a "Little Giant" enterprise indicates the company's strong capabilities in innovation and specialization within its industry [1] - This certification may enhance the company's reputation and potentially attract more investment opportunities [1] - The designation aligns with national policies aimed at supporting small and medium-sized enterprises that demonstrate significant growth potential [1]

Group 1 - Meilixin plans to raise no more than 1.2 billion yuan for semiconductor equipment precision components, communication and automotive parts projects, and to supplement working capital [2] - Olin Bio has prepaid corporate income tax totaling 4.2001 million yuan, with no penalties from tax authorities [3] - Haisen Pharmaceutical's directors and executives plan to reduce their holdings by no more than 124,300 shares, accounting for 0.0816% of the total share capital [4] Group 2 - Aibulu intends to sell 47.4% and 31.6% stakes in its subsidiary Jinque Agriculture for a total of 12.3914 million yuan [5] - Chaoying Electronics plans to increase its Thai subsidiary's capital by 100 million USD for AI high-end PCB expansion [6] - Bona Film Group states that the box office revenue for "Avatar 3" is difficult to predict and the investment return rights are low [7] Group 3 - Junya Technology's PCB products for humanoid robots contribute less than 0.05% to its revenue [9] - Aerospace Electromechanical confirms that its main business does not involve commercial aerospace [10] - Deyi Culture's major shareholder plans to reduce holdings by no more than 2% of shares [11] Group 4 - China National Materials International signed a 2.7 billion yuan engineering contract for a molybdenum mining project [12] - Weiguang Bio plans to sign a 1.13 billion yuan technology cooperation contract for blood products [13] - Suhao Huihong intends to swap assets with its controlling shareholder for a 2.33% stake in Zijin Property Insurance [14] Group 5 - Haike Xinyuan's employee strategic placement plan intends to reduce holdings by no more than 2.5% of shares [15][16] - Taihao Technology's vice president resigns for personal reasons [17] - Huazhu Gaoke plans to establish a joint venture for 3D printing services with a total investment of 100 million yuan [18] Group 6 - Hubei Energy's November power generation was 2.617 billion kWh, a decrease of 17.94% year-on-year [19] - Dong'a Ejiao plans to repurchase shares worth 100 million to 200 million yuan for capital reduction [20] - Longjiang Transportation's shareholder reduced holdings by 1.2% [21] Group 7 - Feilu Co. plans to reduce holdings by no more than 1.02% of shares [22] - Zhongwei Electronics is planning a change in control, leading to a temporary stock suspension [23] - Zhongheng Group's subsidiary received approval for clinical trials of a new cancer drug [24] Group 8 - Guanzhong Ecology's controlling shareholder changed to Deep Blue Financial Whale [25] - Shennong Seed Industry is transferring a 3.8% stake in a subsidiary for 31.9827 million yuan [26] - Sun Cable's major shareholder plans to reduce holdings by no more than 3% of shares [27] Group 9 - Aiwei Electronics' application for issuing convertible bonds has been approved by the Shanghai Stock Exchange [28] - Chongqing Water intends to acquire wastewater treatment projects for 255 million yuan [29] - Boyun New Materials plans to increase its subsidiary's capital by 285 million yuan through debt-to-equity conversion [30] Group 10 - Zhongbai Group is closing unprofitable stores, expecting a loss of approximately 180 million yuan [31] - Changyuan Power's November power generation decreased by 17.88% year-on-year [32]

Group 1 - The company, Haishen Pharmaceutical (001367.SZ), announced that some directors and senior management plan to reduce their holdings of company shares by a total of 124,300 shares, which represents 0.0816% of the company's total share capital [1]

海森药业（001367）(001367.SZ)发布公告，公司部分董事、高级管理人员计划自本公告披露之日起15 个交易日后的3个月内(即2025年12月26日至2026年3月25日)以集中竞价交易方式合计减持公司股份12.43 万股(占公司总股本的0.0816%)。 ...

证券日报网讯12月4日晚间，海森药业（001367）发布公告称，公司近日完成工商变更登记及《公司章 程》备案手续，并取得浙江省市场监督管理局换发的《营业执照》，注册资本由"壹亿伍仟壹佰玖拾贰 万陆仟肆佰肆拾元"变更为"壹亿伍仟贰佰叁拾伍万壹仟贰佰元整"。 ...

格隆汇12月4日丨海森药业(001367.SZ)公布，持有浙江海森药业股份有限公司股份97,680股（占公司总 股本的0.0641%）的董事代亚先生，持有公司股份102,120股（占公司总股本的0.0670%）的副总经理张 胜权先生，持有公司股份102,120股（占公司总股本的0.0670%）的副总经理楼岩军先生，持有公司股份 97,680股（占公司总股本的0.0641%）的财务总监潘爱娟女士，持有公司股份97,680股（占公司总股本 的0.0641%）的董事会秘书胡康康先生，计划自本公告披露之日起15个交易日后的3个月内（即2025年 12月26日至2026年3月25日）以集中竞价交易方式合计减持公司股份124,320股（占公司总股本的 0.0816%）。 ...